Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decrease in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant decline in short interest in April. As of April 15th, there was short interest totalling 7,900 shares, a decline of 86.0% from the March 31st total of 56,600 shares. Based on an average daily volume of 468,400 shares, the short-interest ratio is presently 0.0 days.

Bioxytran Stock Up 3.1 %

OTCMKTS:BIXT traded up $0.00 on Thursday, reaching $0.14. 14,800 shares of the company’s stock traded hands, compared to its average volume of 100,385. The stock has a 50-day simple moving average of $0.12 and a 200-day simple moving average of $0.13. The firm has a market cap of $23.49 million, a PE ratio of -4.50 and a beta of -0.83. Bioxytran has a 12 month low of $0.07 and a 12 month high of $0.54.

Bioxytran (OTCMKTS:BIXT) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($0.01) EPS for the quarter.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.